Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Bas Groot Koerkamp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1917-6973; OpenAlex author ID A5027294559. Sources: ClinicalTrials.gov.

Their work

Papers
158 (first author 4, last author 15)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
418
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 5 papers · 2019: 9 papers · 2020: 13 papers · 2021: 14 papers, 1 trial · 2022: 21 papers · 2023: 21 papers · 2024: 24 papers · 2025: 23 papers · 2026: 26 papers

Papers 50 of 158

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  3. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  4. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  5. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  6. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  7. Neoadjuvant quadruplet chemotherapy PAXG for pancreatic cancer. First author DOI 10.1016/s0140-6736(25)01864-1↗
  8. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Last author DOI 10.1016/s1470-2045(25)00729-6↗
  9. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  10. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  11. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  12. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  13. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  14. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Last author DOI 10.1093/jnci/djag033↗
  15. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  16. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  17. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  18. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  19. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  20. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  21. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  22. Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-026-20413-w↗
  23. ASO Visual Abstract: Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-20555-x↗
  24. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  25. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  26. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  27. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  28. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  29. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  30. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  31. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  32. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Last author DOI 10.1016/j.ejca.2025.116099↗
  33. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  34. Controversies in upper gastrointestinal cancers-the role of radiotherapy in borderline resectable pancreatic cancer. Last author DOI 10.1016/j.esmogo.2025.100232↗
  35. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(25)00261-2↗
  36. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  37. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  38. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  39. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  40. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  41. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  42. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  43. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  44. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  45. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  46. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Last author DOI 10.1097/sla.0000000000006910↗
  47. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  48. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  49. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  50. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗

Trials 1

  1. Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy Principal investigator NCT04881487↗

Closest collaborators

The 25 strongest of 418 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 115 shared papers, 2017–2026 · strength 16.64
  2. Casper H.J. van Eijck · 84 shared papers, 2016–2026 · strength 11.38
  3. Hjalmar C. van Santvoort · 63 shared papers, 2017–2026 · strength 9.09
  4. Johanna W. Wilmink · 59 shared papers, 2018–2026 · strength 8.34
  5. Izaak Quintus Molenaar · 56 shared papers, 2017–2026 · strength 8.02
  6. Ignace H. J. T. de Hingh · 51 shared papers, 2017–2026 · strength 7.10
  7. Bert A. Bonsing · 53 shared papers, 2017–2026 · strength 6.89
  8. Marjolein Y.V. Homs · 35 shared papers, 2019–2026 · strength 5.28
  9. Martijn W.J. Stommel · 35 shared papers, 2019–2026 · strength 5.04
  10. Vincent Erwin de Meijer · 34 shared papers, 2020–2026 · strength 4.98
  11. Lois A. Daamen · 31 shared papers, 2019–2026 · strength 4.80
  12. Judith de Vos‐Geelen · 29 shared papers, 2018–2026 · strength 4.25
  13. Geert Kazemier M · 29 shared papers, 2017–2026 · strength 4.24
  14. Sebastiaan Festen · 29 shared papers, 2020–2026 · strength 4.20
  15. Geertjan van Tienhoven · 31 shared papers, 2017–2026 · strength 4.14
  16. Thomas F. Stoop · 22 shared papers, 2021–2026 · strength 4.03
  17. Quisette P. Janssen · 24 shared papers, 2019–2026 · strength 3.73
  18. Roeland F. de Wilde · 16 shared papers, 2021–2026 · strength 2.95
  19. Hanneke W.M. van Laarhoven · 23 shared papers, 2018–2026 · strength 2.92
  20. Gijs A. Patijn · 21 shared papers, 2017–2026 · strength 2.87
  21. J. Sven D. Mieog · 21 shared papers, 2019–2026 · strength 2.86
  22. Amer H. Zureikat · 13 shared papers, 2022–2026 · strength 2.85
  23. Matthew H. G. Katz · 14 shared papers, 2019–2026 · strength 2.69
  24. Jacob L. van Dam · 18 shared papers, 2018–2026 · strength 2.68
  25. Iris W.J.M. van Goor · 16 shared papers, 2021–2026 · strength 2.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.